metabolic pathway defect which is associated with liver dysfunction in the neonatal period, including: hereditary fructose intolerance, galactosemia due to transferase deficiency and neonatal tyrosinemia, and/or disorder of lipid metabolism
hepatic insufficiency as documented by either a biopsy with cirrhosis and/or marked aberration in synthetic function
renal failure
primary or secondary liver disease, regardless of liver function (includes hepatitis)
use of extracorporeal membrane oxygenation (ECMO)
suspected congenital obstruction of the hepatobiliary tree
documented active infection which may be communicable, including infections hepatitis or HIV
previous receipt of choleretic agents
currently receiving phenobarbital or other barbiturates
history of PNAC
direct bilirubin \>=2 mg/dL at time of enrollment
congenital or acquired anomaly which will require major cardiovascular surgery
